Because Patients Can't Wait®

609-890-3185 | BioNJ@BioNJ.org

Value of Medical Innovation

 

Because Patients Can’t Wait®, BioNJ’s mission is to bolster medical innovation and New Jersey’s life sciences ecosystem. The discovery and development of new therapies and cures allow Patients to live longer, healthier, more productive lives – benefiting the entire healthcare system, New Jersey’s economy and society as a whole.

BioNJ advocates on behalf of our Members to ensure that government continues to invest in the research and development of future medical innovation and that medicines are accessible to Patients in need. We are actively engaged with Patients and Patient advocacy organizations, so that the voice of the Patient and his or her family has an even stronger presence and greater impact in our community.

The medical innovation being developed by our companies is drastically improving the way health care is delivered by saving lives and reducing costly hospitalizations, doctor visits and invasive medical procedures.1

  • Oncology – U.S. cancer survivors have more than doubled to 14.5 million since 1990.
  • Hepatitis C – A once incurable disease now has cure rates above 90%.
  • HIV/AIDS – Once a death sentence, it’s now a chronic manageable condition.
  • Childhood Cancer – 83% of children with cancer now survive, compared to 58% in 1970.
  • Vaccines – More than 730,000 children’s lives have been saved in the last 20 years in the United States because of advances in vaccines.

The Value of Medical
Innovation: The Patients Voice

Because, Patients Can’t Wait®
And, “Time is Precious”

Quick Facts on the Value of Medical Innovation

Click here for a useful one-page primer on the Value of Medical Innovation.  Click here for a one-page resource tool on the Impact of Medical Innovation.



 

Understanding Drug Pricing

Click here for a one-page fact sheet on drug pricing. Click here for a helpful video on “Understanding Step Therapy.”


Cost and Value of Medicines: Let’s Talk About Costs

 

Video: What Is a Results-Based Contract? (Click here)

Reframing the Conversation on Drug Pricing (Click here)

 

1Sources: Alzheimer’s Assoc., American Cancer Society, Biotechnology Innovation Organization, CDC, Celgene, FDA, IMS Institute for Healthcare Informatics, NCI, PhRMA, Truven Health Analytics, Tufts CSDD, et al.